Skip to main content

Table 1 Characteristics of patients with EGFR/ALK co-alterations

From: Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

Patients Age range at diagnosis TNM stage at diagnosis Pathological Metastasis EGFR type ALK type
1 50–70 IV Adenocarcinoma Node, bone 19del STRN-ALK
2 50–70 IV Adenocarcinoma Multiple metastases 19del STRN-ALK
3 50–70 IV Adenocarcinoma bone L858R L1152R
4 50–70 IV Adenocarcinoma Unknown L858R L1152R
5 50–70 IV Adenocarcinoma Brain, bone, liver, node L858R EML4-ALK
6 50–70 IV Adenocarcinoma Pleura, peritoneum, mesentery 19del EML4-ALK
7 50–70 IV Adenocarcinoma Liver, lung, bone, node 19del EML4-ALK
8 50–70 IV Adenocarcinoma Brain, mediastinum, hilum G719C + S768I STRN-ALK
9 50–70 IV Adenocarcinoma Multiple metastases 19del EML4-ALK